Active Biotech (STO:ACTI), a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer, announced on Tuesday that its partner, NeoTX Therapeutics Ltd (NeoTX), will present new preclinical data on the drug candidate naptumomab estafenatox (naptumomab, ANYARA) at the scientific conference at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting being held from 6 November 2019 t0 10 November at National Harbour, Maryland, US.

This poster presentation will highlight preclinical data demonstrating that naptumomab and checkpoint inhibitors work synergistically to induce a prolonged and protective immune response against solid tumours.

Titled 'Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor', the presentation will be made by Meir Azulay PhD on 8 November 2019 from 12:30 to 14:00 hours CET.

In connection with the presentation, the poster will be available on https://www.activebiotech.com.

Naptumomab was licensed from Active Biotech to NeoTX in 2016. NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.

NeoTX is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology.